BTIG Research Cuts GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $80.00

GE HealthCare Technologies (NASDAQ:GEHC) had its target price cut by BTIG Research from $85.00 to $80.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently issued reports on GEHC. Mizuho dropped their price target on shares of GE HealthCare Technologies from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Stifel Nicolaus boosted their target price on shares of GE HealthCare Technologies from $95.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and boosted their target price for the company from $73.00 to $77.00 in a research report on Thursday, January 15th. Citigroup dropped their target price on shares of GE HealthCare Technologies from $88.00 to $84.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Finally, The Goldman Sachs Group dropped their target price on shares of GE HealthCare Technologies from $97.00 to $81.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Hold” and an average price target of $80.67.

GE HealthCare Technologies Stock Up 0.3%

Shares of NASDAQ GEHC opened at $61.03 on Wednesday. The company has a market capitalization of $27.76 billion, a P/E ratio of 14.60, a price-to-earnings-growth ratio of 1.38 and a beta of 0.75. GE HealthCare Technologies has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.13 and a current ratio of 1.22. The company’s 50 day moving average price is $73.28 and its 200-day moving average price is $77.52.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). The firm had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Equities analysts forecast that GE HealthCare Technologies will post 4.84 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, April 3rd will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Thursday, April 2nd. GE HealthCare Technologies’s payout ratio is presently 3.35%.

Insider Activity at GE HealthCare Technologies

In related news, CFO James Saccaro bought 3,310 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were bought at an average price of $60.60 per share, for a total transaction of $200,586.00. Following the transaction, the chief financial officer directly owned 87,471 shares of the company’s stock, valued at approximately $5,300,742.60. The trade was a 3.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter J. Arduini bought 4,169 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were bought at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the transaction, the chief executive officer directly owned 259,424 shares in the company, valued at $15,544,686.08. This trade represents a 1.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,229 shares of company stock worth $556,180 in the last quarter. Company insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in GE HealthCare Technologies by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock worth $4,287,658,000 after buying an additional 267,058 shares during the last quarter. Auto Owners Insurance Co raised its holdings in GE HealthCare Technologies by 9,525.4% during the fourth quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after buying an additional 33,629,559 shares during the last quarter. Dodge & Cox raised its holdings in GE HealthCare Technologies by 13.4% during the fourth quarter. Dodge & Cox now owns 31,211,229 shares of the company’s stock worth $2,559,945,000 after buying an additional 3,693,918 shares during the last quarter. Capital Research Global Investors raised its holdings in GE HealthCare Technologies by 1.6% during the fourth quarter. Capital Research Global Investors now owns 25,362,352 shares of the company’s stock worth $2,080,248,000 after buying an additional 389,796 shares during the last quarter. Finally, State Street Corp raised its holdings in GE HealthCare Technologies by 2.0% during the fourth quarter. State Street Corp now owns 20,049,677 shares of the company’s stock worth $1,644,475,000 after buying an additional 401,932 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

More GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Insiders are buying shares — CEO Peter Arduini, CFO James Saccaro and director Frank R. Jimenez increased positions (multiple Form 4 filings), which investors often interpret as management confidence in the company’s outlook. Read More. • Read More. • Read More.
• Positive Sentiment: Heavy call-option buying — an unusual surge in call volume suggests short-term bullish/speculative interest that can amplify upside moves. (No article link available)
• Neutral Sentiment: Wells Fargo lowered its price target to $75 but kept an overweight rating, signaling upside exists vs. current levels while tempering near-term expectations. Read More.
• Neutral Sentiment: Operational changes — GEHC announced a reorganization (Imaging + Advanced Visualization) and executive moves intended to improve execution; benefits could take multiple quarters to materialize. Read More.
• Negative Sentiment: Guidance cut and margin pressure — management trimmed FY26 EPS guidance to $4.80–5.00, citing inflation, higher component and freight costs and supply issues; this is the core reason for recent downside pressure. Read More.
• Negative Sentiment: Mixed Q1 results — revenue beat (~$5.13B) but EPS missed ($0.99 vs. $1.07 est.) and margins compressed, reinforcing short?term risk to earnings. Read More.
• Negative Sentiment: Analyst downgrades / price?target cuts — Citigroup, JPMorgan and others trimmed targets and ratings (e.g., PTs cut to ~$65–75), pulling sell?side support lower and contributing to volatility. Read More.
• Negative Sentiment: Investor litigation inquiry — a Johnson Fistel investigation adds headline and legal risk that could increase volatility. Read More.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.